Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rafael Holdings Inc (RFL)

Rafael Holdings Inc (RFL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,373
  • Shares Outstanding, K 51,771
  • Annual Sales, $ 920 K
  • Annual Income, $ -30,520 K
  • EBIT $ -26 M
  • EBITDA $ -23 M
  • 60-Month Beta 0.69
  • Price/Sales 69.44
  • Price/Cash Flow N/A
  • Price/Book 0.64

Options Overview Details

View History
  • Implied Volatility 339.74% (-40.61%)
  • Historical Volatility 53.94%
  • IV Percentile 70%
  • IV Rank 24.34%
  • IV High 1,250.29% on 08/13/25
  • IV Low 46.81% on 11/18/25
  • Expected Move (DTE 9) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 26
  • Volume Avg (30-Day) 180
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 658
  • Open Int (30-Day) 14,651
  • Expected Range 1.5500 to 1.5500

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1700 +32.48%
on 11/26/25
1.5700 -1.27%
on 12/09/25
+0.2600 (+20.16%)
since 11/07/25
3-Month
1.1700 +32.48%
on 11/26/25
1.7000 -8.82%
on 09/18/25
+0.1100 (+7.64%)
since 09/09/25
52-Week
1.1700 +32.48%
on 11/26/25
3.1900 -51.41%
on 06/10/25
-0.3600 (-18.85%)
since 12/09/24

Most Recent Stories

More News
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for  Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation...

RFL : 1.5500 (+15.67%)
Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the...

RFL : 1.5500 (+15.67%)
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPCâ„¢ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

First data on treatment of NPC1 with Trappsol ® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients 1 showed...

RFL : 1.5500 (+15.67%)
Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation...

RFL : 1.5500 (+15.67%)
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data

RFL : 1.5500 (+15.67%)
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

RFL : 1.5500 (+15.67%)
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

RFL : 1.5500 (+15.67%)
Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential...

RFL : 1.5500 (+15.67%)
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

RFL : 1.5500 (+15.67%)
Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

RFL : 1.5500 (+15.67%)

Business Summary

Rafael Holdings Inc. manufactures metabolic oncology drugs to treat cancer. The company's product pipeline consists of CPI-613, CPI-618, CPI-1826 and CPI-3220 which are in clinical stages. Rafael Holdings Inc. is based in Newark, United States.

See More

Key Turning Points

3rd Resistance Point 1.8096
2nd Resistance Point 1.6898
1st Resistance Point 1.6199
Last Price 1.5500
1st Support Level 1.4302
2nd Support Level 1.3104
3rd Support Level 1.2405

See More

52-Week High 3.1900
Fibonacci 61.8% 2.4184
Fibonacci 50% 2.1800
Fibonacci 38.2% 1.9416
Last Price 1.5500
52-Week Low 1.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar